About
Founded 2024 · California
We publish.
We do not prescribe.
Aeterna Method is an independent editorial practice – writers, researchers, and editors who read the literature on peptide therapeutics and longevity science, and publish what we find. We are not a clinic, and we do not prescribe, supply, or treat. Our work exists to make the field legible to the people who will use it – practitioners, members, and the curious – and to the clinicians who care for them.
The standing
Three reasons hold us in place
The classical triad: what we feel, what we reason, what we stand for. We use it because it disciplines us. Each of the three is a check on the other two.
πάθος
Pathos · the why
The field that deserves better
Peptide therapeutics are arriving in clinics ahead of the literacy required to use them well. The result is a market of breathless claims and a corresponding silence from serious practitioners. We started Aeterna because that silence has a cost, paid by the patient who reads it as permission, and by the clinician who has nowhere to send them.
λόγος
Logos · the reasoning
Evidence first, language second
Every monograph cites primary sources. Every protocol is tied to a published trial or to a clearly marked clinical practice. Where evidence is absent, we say so; where it is contested, we present both sides. Plain language is a discipline, not a style, and it forces us to know what we mean before we write it.
ἔθος
Ethos · the character
The same standard, publicly
We hold ourselves to one rule: we will not publish anything we would not be willing to defend before a practicing clinician. No private channel, no tier of privileged claims for paying members, no marketing copy that contradicts the monograph. The standard is the same for the open Compendium and the membership curriculum.
Problem
This matters!
Longevity medicine sits in an unusual place because it’s old enough to have a literature, new enough to lack consensus, and popular enough to attract people who do not read either.
Most of what is sold as longevity today is marketing wrapped around a molecule. We would like to put the science back in front.
Audience
For whom, and for whom not
A defined audience produces better work. The list below is short on both sides because we would rather be useful to a few than agreeable to everyone.
+ for whom
People who arrive having already read
01
Practitioners who want a single trusted source for peptide protocols and monographs.
02
Curious patients who have read the studies their physician has not yet had time to.
03
Athletes, surgeons, and the post-operative, anyone whose recovery is a project, not a wait.
04
Members over 30 who treat their next 40 years as a discipline.
+ for whom not
Anyone hoping for a shortcut
01
Readers who want a single hack or supplement that replaces sleep, training, and diet.
02
Anyone seeking prescription or supply outside a licensed clinician’s care. We do not prescribe.
03
Patients searching for a clinic. We are a publication, not a practice; we equip your physician; we do not replace one.
04
Readers who prefer certainty to evidence. We will often answer with a qualified “it depends”.
Commitments
Four things we have agreed to not do
A short list of constraints, formally adopted. They are negative commitments by design, easier to keep, harder to forget.
I
No private evidence
The membership curriculum contains no claim that the open Compendium would not also support. Members are here for curation, synthesis, and editorial time.
III
II
No celebrity endorsements
The reputational halo of the famous is not a substitute for evidence. We do not solicit them, and we decline when they are offered.
II
III
No off-labelpersuasion
Where a molecule has regulatory approval for one indication and emerging evidence for another, we report both. We do not encourage members to use off-label; we equip their physicians to assess it.
IV
No perpetual protocols
Every protocol we publish includes its endpoint. Indefinite intervention is a market preference, not a clinical one. We treat the absence of a stop date as a defect in the protocol.
If this resembles the community you have been looking for, begin.
The parts of our knowledge base are open to anyone without an account. Membership is a separate matter: measured, deliberate, and not for everyone. Both are doors into the same building.
Aeterna BioLab is a separate research-materials store at aeternabiolab.com. Its company information page describes its research-use scope and provides contact details for documentation enquiries.